8-K: Recursion Pharmaceuticals Announces Pipeline Updates and Partnership Progress at Download Day

Recursion Pharmaceuticals provided updates on its clinical pipeline, including seven expected clinical trial readouts within approximately 18 months, and highlighted advancements in its partnerships and platform technology at its Download Day investor meeting.

Summary

• Recursion Pharmaceuticals held its Download Day investor meeting on June 24, 2024, providing updates on its clinical pipeline and partnerships.
• The company anticipates seven clinical trial readouts within the next 18 months, including Phase 2 data for REC-994 in Cerebral Cavernous Malformation expected in September 2024.
• Preliminary Phase 2 data readouts are expected for REC-2282 in Neurofibromatosis Type 2 in the fourth quarter of 2024, and for REC-4881 in Familial Adenomatous Polyposis and Advanced AXIN1/APC-Mutant Cancers in the first half of 2025.
• Recursion plans to initiate a Phase 2 study for REC-3964 in Clostridioides difficile Infection in the fourth quarter of 2024, with preliminary data expected by the end of 2025.
• An IND submission for RBM39 in Advanced HR-Proficient Cancers is planned for the third quarter of 2024, with Phase 1/2 initiation in the fourth quarter of 2024 and Phase 1 dose-escalation data by the end of 2025.
• An IND submission for Target Epsilon in Fibrotic Diseases is expected in early 2025, with Phase 1 healthy volunteer study data by the end of 2025.
• Recursion has delivered multiple data packages to Bayer and initiated their first joint oncology project, which is expected to advance rapidly.
• Bayer will be the first external beta-user of Recursion's LOWE software for drug discovery and development.
• The company is on track to complete 25 unique multi-modal data packages for Bayer in the third quarter of 2024.
• Recursion has achieved an estimated 90 times the amount of lab throughput over a manual approach through ADME industrialization.
• The company has built its first genome-scale transcriptomics knockout map.
• Multimodal mapping has enabled a 90% success rate in predicting compounds that failed later disease-relevant assays and a 60% success rate in predicting compounds that passed later disease-relevant assays in internal tests.
• Recursion has a partnership with Helix, bringing hundreds of thousands of unique de-identified patient records across diverse therapeutic areas.
• Recursion believes it is uniquely positioned to take advantage of the transition of BioTech to TechBio due to its data, compute, and automation capabilities.

Sentiment

Score: 8

Explanation: The document presents a highly positive outlook with significant advancements in pipeline, partnerships, and platform technology. The company's focus on AI and data-driven approaches, combined with strong financial backing, suggests a promising future. However, the inherent risks in drug development temper the overall sentiment.

Positives

• The company has a robust pipeline with multiple clinical readouts expected in the near term.
• The partnership with Bayer is progressing well, with the initiation of a joint oncology project and Bayer becoming the first beta-user of LOWE.
• Recursion's platform is showing significant improvements in throughput and predictive capabilities.
• The company is leveraging large datasets and advanced AI/ML technologies to accelerate drug discovery.
• The company has a strong financial position with approximately $296M in cash as of Q1 2024.

Negatives

• The document does not explicitly mention any negative aspects of the company's performance or outlook.
• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Risks

• The company faces challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs.
• There is a risk of failure at any stage of drug development due to lack of sufficient efficacy, safety considerations, or other factors.
• The company's ability to leverage and enhance its drug discovery platform is crucial for its success.
• The company's ability to obtain financing for development activities and other corporate purposes is a risk.
• The success of collaboration activities is not guaranteed.
• The company's ability to obtain regulatory approval of, and ultimately commercialize, drug candidates is a risk.
• The company faces risks related to intellectual property protections, cyberattacks, and the ability to attract and retain key employees.
• Macroeconomic issues such as inflation could impact the company's performance.

Future Outlook

Recursion anticipates multiple clinical trial readouts, continued partnership advancements, and further development of its platform technology. The company expects to leverage its AI/ML capabilities to accelerate drug discovery and development.

Management Comments

• Chris Gibson, Ph.D., Co-Founder and CEO of Recursion, stated that various industries are increasingly embracing AI/ML solutions, including the drug discovery space.
• Chris Gibson highlighted the company's strong leadership position by building technological and operational capabilities to expand its internal pipeline and deliver for external partners.
• Recursion management believes the transformation of BioPharma through AI is inevitable.

Industry Context

The announcement highlights the growing trend of integrating AI and machine learning into drug discovery and development. Recursion is positioning itself as a leader in the TechBio space, leveraging its platform to accelerate the identification and development of new therapeutics. The company's partnerships with major pharmaceutical companies like Bayer and Roche/Genentech demonstrate the industry's increasing interest in AI-driven drug discovery platforms.

Comparison to Industry Standards

• Recursion's claim of achieving 90x throughput over manual approaches in ADME industrialization is significantly higher than traditional methods, which typically involve manual processes and lower throughput.
• The company's ability to predict compounds that failed later disease-relevant assays with 90% success and compounds that passed with 60% success is a notable improvement over traditional drug discovery methods, which often have lower success rates in early-stage predictions.
• The company's timeline of approximately 18 months from new biology to development candidate is significantly faster than the industry average of 45 months, indicating a more efficient drug discovery process.
• Recursion's approach of using multimodal data and machine learning to identify novel targets and optimize chemistry is a departure from traditional methods that rely on more linear and time-consuming processes.
• The company's use of a large-scale supercomputer, BioHive-2, positions it as a leader in computational drug discovery, as many companies do not have access to such advanced computing resources.
• The partnerships with companies like Bayer and Roche/Genentech are comparable to other collaborations in the industry, but Recursion's focus on AI and data-driven approaches sets it apart.

Stakeholder Impact

• Shareholders can expect potential value creation from the company's pipeline advancements and partnerships.
• Employees may benefit from the company's growth and innovation.
• Customers and patients may benefit from the development of new therapeutics.
• Partners may benefit from the company's platform and data capabilities.
• Creditors may benefit from the company's strong financial position.

Next Steps

• Recursion will continue to advance its clinical programs, with multiple data readouts expected in the next 18 months.
• The company will continue to develop its partnerships, particularly with Bayer and Roche/Genentech.
• Recursion will continue to enhance its platform technology, including the development of multiomics foundation models.
• The company will explore additional partnership opportunities in large, intractable areas of biology.
• Recursion will continue to leverage its data and AI capabilities to accelerate drug discovery and development.

Key Dates

Keywords

drug discovery, AI, machine learning, clinical trials, partnerships, pipeline, genomics, oncology, data, biotech, TechBio, LOWE, RBM39, REC-994, REC-2282, REC-4881, REC-3964, fibrotic diseases